We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

31 hedge funds and large institutions have $3.65M invested in Cellectar Biosciences in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

3% more funds holding

Funds holding: 30 → 31 (+1)

0% less ownership

Funds ownership: 0.04% → 0.04% (-0%)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

22% less capital invested

Capital invested by funds: $4.69M → $3.65M (-$1.04M)

Holders
31
Holders Change
+1
Holders Change %
+3.33%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$32.9K
2
Renaissance Technologies
Renaissance Technologies
New York
+$18.9K
3
UBS Group
UBS Group
Switzerland
+$11K
4
VF
Virtu Financial
New York
+$7.28K
5
Jane Street
Jane Street
New York
+$6.43K

Top Sellers

Rank Fund Capital Flow
1
1WM
1900 Wealth Management
Texas
-$83K
2
BlackRock
BlackRock
New York
-$65.8K
3
SCM
Sterneck Capital Management
Missouri
-$21K
4
Franklin Resources
Franklin Resources
California
-$18.6K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$1.63M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$708K – – –
BlackRock
3
BlackRock
New York
$232K -$65.8K -461 -19%
WVP
4
Worth Venture Partners
New Jersey
$225K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$179K +$1.14K +8 +0.5%
MS
6
Maven Securities
Jersey
$162K – – –
ACM
7
ACT Capital Management
Pennsylvania
$88K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$67K +$18.9K +132 +31%
State Street
9
State Street
Massachusetts
$63K +$3.29K +23 +5%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$49K -$286 -2 -0.5%
Franklin Resources
11
Franklin Resources
California
$42K -$18.6K -130 -27%
DCM
12
Difesa Capital Management
New York
$40K – – –
Northern Trust
13
Northern Trust
Illinois
$39K – – –
Citadel Advisors
14
Citadel Advisors
Florida
$28K +$32.9K +230 New
CAM
15
Cozad Asset Management
Illinois
$23K – – –
UBS Group
16
UBS Group
Switzerland
$16K +$11K +77 +140%
Commonwealth Equity Services
17
Commonwealth Equity Services
Massachusetts
$14K – – –
MWM
18
Modera Wealth Management
New Jersey
$8K – – –
TRCT
19
Tower Research Capital (TRC)
New York
$7K +$3.86K +27 +96%
CB
20
Commerce Bank
Missouri
$6K – – –
VF
21
Virtu Financial
New York
$6K +$7.28K +51 New
SC
22
Scotia Capital
Ontario, Canada
$5K -$143 -1 -3%
Jane Street
23
Jane Street
New York
$5K +$6.43K +45 New
PFS
24
Prospera Financial Services
Texas
$2K -$4K -28 -61%
Osaic Holdings
25
Osaic Holdings
Arizona
$2K -$143 -1 -6%
1
2

CLRB Hedge Fund Activity: Q2 2022 in Review

31 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2022, worth a combined $3.65M — down 22% from $4.69M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CLRB positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $32.9K. The largest seller was 1900 Wealth Management, exiting entirely with an estimated $83K sold.

  • 31 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2022, up from 30 in Q1 2022.
  • Funds reported $3.65M of Cellectar Biosciences stock for Q2 2022, down 22% quarter-over-quarter.
  • 4 funds opened new Cellectar Biosciences positions in Q2 2022 and 3 closed out, a net change of +1 holder.
  • The largest Cellectar Biosciences buyer in Q2 2022 was Citadel Advisors, an estimated $32.9K added.
  • The largest Cellectar Biosciences seller in Q2 2022 was 1900 Wealth Management, an estimated $83K sold.

Based on aggregated 13F filings for Q2 2022.